Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: A nuclear microscopic study

Brain Research

Volumn 735, Issue 1, 1996, Pages 149-153

  He, Y ^a   Thong, P S P ^a   Lee, T ^a   Leong, S K ^a   Shi, C Y ^a   Wong, P T H ^a   Yuan, S Y ^a   Watt, F ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

6 Hydroxydopamine; Iron; Parkinson's disease; Rat; Substantia nigra

Indexed keywords

AMPHETAMINE; CALCIUM; COPPER; IRON; MAGNESIUM; OXIDOPAMINE; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

EID: 0030607202     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00313-7     Document Type: Article

References (19)

1. [1] Ben-Shachar, D., Riederer, P. and Youdim, M.B.H., Iron-melanin interaction and lipid peroxidations: implications for Parkinson's disease, J. Neurochem., 57 (1991) 1609-1614.
2. [2] Ben-Shachar, D., Eshel, G., Finberg, J.P.M. and Youdim, M.B.H., The iron chelator desferrioxamine (Desferal) retards 6-hydroxy-dopamine-induced degeneration of nigrostriatal dopamine neurons, J. Neurochem., 56 (1991) 1441-1444.
3. [3] Dexter, D.T., Carter, C.J., Wells, F.R., Javoy-Agid, Y., Lees, A., Jenner, P. and Marsden, C.D., Basal liquid peroxidation in substania nigra is increased in Parkinson's disease, J. Neurochem., 52 (1989) 381-389.
4. [4] Dexter, D.T., Wells, F.R., Lees, A.J., Agid, Y., Jenner, P. and Marsden, C.D., Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease, J. Neurochem., 52 (1989) 1830-1836.
5. [5] Dexter, D.T., Carayon, A., Javoy-Agid, F., Agid Y., Wells, F.R., Daniel, S.E., Lees A.J., Jenner, P. and Marsden, C.D., Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia, Brain, 114 (1991) 1953-1975.
6. [6] Grime, G.W., Dawson, M., A PC-based data acquisition package for nuclear microbeam systems, Nucl. Instr. Methods, B89 (1994) 223-228.
7. [7] Good, P.F., Olanow, C.W. and Perl, D.P., Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study, Brain Res., 593 (1992) 343-346.
8. [8] Oestreicher, E., Sengstock, G.J., Riederer, P., Olanow, C.W., Dunn, A.J. and Arendash, G.W., Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study, Brain Res., 660 (1994) 8-18.
9. [9] Olanow, C.W. and Drayer, B., Brain iron: MRI studies in Parkinson's syndrome. In S. Fahn, C.D. Marsden, D. Calne and M. Goldstein (Eds.), Recent Developments in Parkinson's Disease, Vol. II, Macmillan Healthcare Information, Florham Park, New Jersey, 1987, pp. 135-143.
10. [10] Paxinos, G. and Watson, C. The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1986.
11. [11] Perry, T.L. and Yong, V.W., Idiopathic Parkinson's disease, progressive supraunclear palsy and glutathione metabolism in the substantia nigra of patients, Neurosci. Lett., 67 (1986) 267-274.
12. [12] Riederer, P., Sofic, E., Rausch, W.D., Kruzik, P. and Youdim, M.B.H., Dopaminforschung heute und morgen-L-DOPA in der Zukunft. In In P. Riederer and P. Umek (Eds.), L-DOPA-Substitution der Parkinson-Krankheit, Geschichte-Gegenwart-Zukunft, Springer, New York, 1985, pp. 127-144.
13. [13] Riderer, P., Sofic, E., Rausch, W.D., Schmidt, B., Reynolds, G.P., Jellinger, K. and Adam, M.B.H., Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains, J. Neurochem., 52 (1989) 515-520.
14. [14] Sofic, E., Paulus, W., Jellinger, K., Riederer, P. and Youdim, M.B.H., Selective increase of iron in substantia nigra zona compacta of parkinsonian brains, J. Neurochem., 56 (1991) 978-982.
15. [15] Stephen, B.D., Ian, Q.W., Derek, C.R. and Graham, H.J., Dopamine-rich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with 6-hydroxy-dopamine lesions, Brain Res., 415 (1987) 63-78.
16. [16] Uitti, R.J., Rajput, A.H., Rozdilsky, B., Bickis, M., Wollin, T. and Yuen, W.K., Regional metal concentrations in Parkinson's disease, other chronic neurological disease, and control brains, Can. J. Neurol. Sci., 16 (1989) 310-314.
17. [17] Ungerstedt, U., 6-Hydroxy-dopamine induced degeneration of central monoamine neurons, Eur. J. Pharmacol., 5 (1968) 107-110.
18. [18] Watt, F., Orlic, I., Loh, K.K., Sow, C.H., Thong, P., Liew, S.C., Osipowicz, T., Choo, T.F., Tang, S.M., The National University of Singapore nuclear microscope facility, Nucl. Instr. Methods, B85 (1994) 708-715.
19. [19] Watt, F. and Grime, G.W., The high energy ion microprobe. In In S.A.E. Johansson, J.L. Campbell and K.G. Malmqvist (Eds.), Particle Induced X-ray Emission Spectrometry, Wiley, New York, 1995, pp. 101-165.